-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

Benzinga·08/20/2026 18:45:54
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $45 to $58.